13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE Filed 2025-04-03 Event 2025-04-01 SEC 0001214659-25-005391 →

TANG CAPITAL MANAGEMENT LLC Allakos Inc.

Stake: 9.60% Shares: 8,693,687 CUSIP: 01671P100 Class: Common Stock, par value $0.001 per share

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is amended by adding the following: Merger Agreement and Related Transactions: On April 1, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Concentra and Concentra Merger Sub III, Inc., a wholly owned subsidiary of Concentra ("Merger Sub"). The Merger Agreement provides for, among other things, (i) the acquisition of all the Issuer's outstanding shares of Common Stock by Concentra through a cash tender offer (the "Offer") by Merger Sub, for a price per share of the Common Stock of $0.33 in cash, and (ii) the merger of Merger Sub with and into the Issuer (the "Merger") with the Issuer surviving the Merger. Closing of the Offer is subject to certain conditions, including that the number of shares of Common Stock validly tendered equals at least one share more than 50% of all shares of Common Stock then issued and outstanding as of the expiration of the Offer, the Closing Net Cash (as defined in the Merger Agreement) shall be no less than $35.5 million, and other customary conditions. The foregoing description of the Merger Agreement and related transactions does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which is attached as Exhibit 2.1 to the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on April 2, 2025. Guaranty: Concurrently with the execution of the Merger Agreement, and as a condition and inducement to the Issuer's willingness to enter into the Merger Agreement, Tang Capital Partners, LP delivered to the Issuer a duly executed limited guaranty dated as of the date of the Merger Agreement, in favor of the Issuer, in respect of certain of Concentra and the Merger Sub's obligations arising under, or in connection with, the Merger Agreement. Certain obligations under the limited guaranty are subject to a cap of $30.6 million, which includes certain enforcement costs, under the Merger Agreement.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
6 13D/G filings on this issuer
5 other filings besides this one
Filer Track Record
11 filings by this filer
10 other filings in the data moat
Short Interest
Not in latest FINRA snapshot

Other 13D/G Filings on Allakos Inc.

FiledFormFilerStakeShares
2025-05-19 SCHEDULE TANG CAPITAL MANAGEMENT LLC 100.00% 10,000 view →
2021-03-11 SC New Enterprise Associates 16, L.P. view →
2021-01-08 SC RiverVest Venture Fund III, L.P. view →
2021-01-06 SC Alta Partners VIII, L.P. view →
2020-01-28 SC Alta Partners VIII, L.P. view →

Other Filings by TANG CAPITAL MANAGEMENT LLC

FiledFormIssuerStakeShares
2026-07-27 SCHEDULE 13D/A Nano Dimension Ltd. 16,715,812 view →
2026-06-30 SCHEDULE 13D Nano Dimension Ltd. NNDM 14,292,813 view →
2026-06-29 SCHEDULE 13G Boundless Bio, Inc. BOLD view →
2026-06-10 SCHEDULE 13G Fulcrum Therapeutics, Inc. FULC view →
2026-06-04 SCHEDULE 13D/A Aurinia Pharmaceuticals Inc. AUPH 10.00% 13,044,106 view →
2026-05-13 SCHEDULE 13D/A Kezar Life Sciences, Inc. 0 view →
2025-09-03 SCHEDULE iTeos Therapeutics, Inc. 100.00% 10,000 view →
2025-05-19 SCHEDULE Allakos Inc. 100.00% 10,000 view →
2025-03-04 SCHEDULE Aurinia Pharmaceuticals Inc. AUPH 7.30% 10,029,500 view →
2025-02-27 SCHEDULE ACELYRIN, Inc. 7.30% 7,298,328 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →